Literature DB >> 9649212

Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

S Dionne1, I D D'Agata, J Hiscott, T Vanounou, E G Seidman.   

Abstract

IBD is associated with an increased activation of intestinal immune cells, which causes overproduction of proinflammatory cytokines such as IL-1beta. IL-1beta is implicated in mediating the sustained inflammatory response. IL-1 receptor antagonist (IL-1Ra), the naturally occurring inhibitor of IL-1, has been shown to have beneficial effects in experimental models of colitis. In this study we investigated the hypothesis that an imbalance between IL-1 and IL-1Ra exists in IBD by measuring their secretion by explant cultures of colonic biopsies. Freshly homogenized biopsies from involved tissue in IBD patients exhibited significantly lower IL-1Ra/IL-1beta ratios than control and uninvolved IBD mucosal tissue. Using explant cultures, in vitro production of IL-1beta and IL-1Ra increased progressively during the 4-18-h culture periods. IL-1beta secretion was higher in supernatants from involved Crohn's disease (CD) and ulcerative colitis tissue compared with control tissue, and IL-1beta levels increased with severity of inflammation. IL-1Ra secretion was not elevated in involved IBD samples, but significantly higher levels were released when moderate to severely involved tissue samples were compared with noninflammatory controls. Similar to freshly homogenized tissue, explant studies showed that the IL-1Ra/IL-1beta ratios were significantly decreased in involved IBD tissue, but not in uninvolved CD or inflammatory control specimens. These data support the hypothesis of an imbalance between IL-1beta and IL-1Ra in IBD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649212      PMCID: PMC1904987          DOI: 10.1046/j.1365-2249.1998.00595.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Immunogenetics of cytokines. Relevance for future research on inflammatory bowel disease.

Authors:  I Koutroubakis; J B Crusius; A S Peña
Journal:  Scand J Gastroenterol       Date:  1995-12       Impact factor: 2.423

Review 2.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

3.  Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies.

Authors:  S Dionne; J Hiscott; I D'Agata; A Duhaime; E G Seidman
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

4.  Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor.

Authors:  J G Giri; R C Newton; R Horuk
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

5.  Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells.

Authors:  J Rugtveit; G Haraldsen; A K Høgåsen; A Bakka; P Brandtzaeg; H Scott
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

6.  5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.

Authors:  Y R Mahida; C E Lamming; A Gallagher; A B Hawthorne; C J Hawkey
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

7.  Tumor necrosis factor-alpha inhibits lipid and lipoprotein transport by Caco-2 cells.

Authors:  M Mehran; E Seidman; R Marchand; C Gurbindo; E Levy
Journal:  Am J Physiol       Date:  1995-12

8.  Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guérin.

Authors:  B Sander; U Skansén-Saphir; O Damm; L Håkansson; J Andersson; U Andersson
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

Review 9.  Biologic basis for interleukin-1 in disease.

Authors:  C A Dinarello
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.

Authors:  M Ligumsky; P L Simon; F Karmeli; D Rachmilewitz
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

View more
  28 in total

1.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

2.  Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease.

Authors:  Doris Meister; Subrata Ghosh
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

Review 3.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 4.  Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

Authors:  Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

5.  Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Masami Yamada; Yoshihiko Sato; Ken Takeuchi; Tatsuo Tanaka; Kenji Kondo; Masataka Kikuyama; Yasuhiko Maruyama; Yasushi Iwaoka; Akiko Nakamura; Kazuhisa Hirayama; Abby R Saniabadi; Fumitoshi Watanabe
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis.

Authors:  N P Barlo; C H M van Moorsel; N M Korthagen; M Heron; G T Rijkers; H J T Ruven; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

7.  Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice.

Authors:  Kazuhiko Ono; Satoshi Nimura; Yuko Hideshima; Kazuki Nabeshima; Manabu Nakashima
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

8.  Metformin exerts anti-inflammatory effects on mouse colon smooth muscle cells in vitro.

Authors:  Ahmed Al-Dwairi; Mohammad Alqudah; Othman Al-Shboul; Mahmoud Alfaqih; Dana Alomari
Journal:  Exp Ther Med       Date:  2018-05-25       Impact factor: 2.447

Review 9.  Role of cytokines in inflammatory bowel disease.

Authors:  Fausto Sanchez-Munoz; Aaron Dominguez-Lopez; Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

10.  Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.

Authors:  Andrew W Stadnyk; Moorix M W Yeung; Sen Rong Yan
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.